Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

Frank Breitenbuecher, Boyka Markova, Stefan Kasper, Birgit Carius, Torsten Stauder, Frank D. Böhmer, Kristina Masson, Lars Rönnstrand, Christoph Huber, Thomas Kindler, Thomas Fischer

Blood (2009) 113 (17): 4063–4073.

https://doi.org/10.1182/blood-2007-11-126664

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

Frank Breitenbuecher, Susanne Schnittger, Rebekka Grundler, Boyka Markova, Birgit Carius, Alexandra Brecht, Justus Duyster, Torsten Haferlach, Christoph Huber, Thomas Fischer

Blood (2009) 113 (17): 4074–4077.

https://doi.org/10.1182/blood-2007-11-125476

Published: 2009

Journal Articles

3,4-Diarylmaleimides Effectively Inhibit Proliferation of FLT3-ITD-Positive Leukemic Cells, Induce Apoptosis and Show Additive Effects in Combination with Chemotherapeutic Drugs.

Florian H. Heidel, MD, Daniel B. Lipka, MD, Fian K. Mirea, Boyka Markova, PhD, Christian Peifer, PhD, Jan-Peter Kramp, PhD, Stanislav Plutizki, Christoph Huber, MD, Gerd Dannhardt, PhD, Thomas Fischer, MD

Blood (2007) 110 (11): 1605.

https://doi.org/10.1182/blood.V110.11.1605.1605

Published: 2007

Journal Articles

The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.

Daniel B. Lipka, MD, Linda S. Hoffmann, MSc, Florian Heidel, MD, Boyka Markova, PhD, Stefan Kasper, MD, Frank Breitenbuecher, PhD, Thomas Kindler, MD, Ross Levine, MD, Joseph Elliot, PhD, Christoph Huber, MD, Thomas Fischer, MD

Blood (2007) 110 (11): 3544.

https://doi.org/10.1182/blood.V110.11.3544.3544

Published: 2007

Journal Articles

Identification of a Novel Pathway in BCR/ABL Signal Transduction Involving Akt-Independent Activation of PLC-gamma/mTOR/p70-S6K.

Boyka Markova, Christoph Huber, Thomas Fischer

Blood (2006) 108 (11): 2120.

https://doi.org/10.1182/blood.V108.11.2120.2120

Published: 2006

NARROW

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

3,4-Diarylmaleimides Effectively Inhibit Proliferation of FLT3-ITD-Positive Leukemic Cells, Induce Apoptosis and Show Additive Effects in Combination with Chemotherapeutic Drugs.

The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.

Identification of a Novel Pathway in BCR/ABL Signal Transduction Involving Akt-Independent Activation of PLC-gamma/mTOR/p70-S6K.

Email alerts

ASH Publications

American Society of Hematology

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

3,4-Diarylmaleimides Effectively Inhibit Proliferation of FLT3-ITD-Positive Leukemic Cells, Induce Apoptosis and Show Additive Effects in Combination with Chemotherapeutic Drugs.

The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.

Identification of a Novel Pathway in BCR/ABL Signal Transduction Involving Akt-Independent Activation of PLC-gamma/mTOR/p70-S6K.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only